Triple antiviral drug shows early promise in COVID-19 trial

Triple antiviral drug shows early promise in COVID-19 trial

Triple antiviral drug shows early promise in COVID-19 trial

A triple-drug combination of antiviral medicines helped relieve symptoms in patients with mild to moderate COVID-19 infection and swiftly reduced the amount of virus in their bodies, according to results of a small trial in Hong Kong.

The trial, which involved 127 patients, compared those given the combination drug – made up of the HIV medicine lopinavir-ritonavir, the hepatitis drug ribavirin, and the multiple sclerosis treatment interferon-beta – with a control group given just the HIV drug.

The findings, published in The Lancet medical journal, showed that on average, people who got the triple-drug reached the point of no detectable virus five days earlier than those in the control group – at 7 days versus 12 days.

“Our trial demonstrates that early treatment of mild to moderate COVID-19 with a triple combination of antiviral drugs may rapidly suppress the amount of virus in a patient’s body, relieve symptoms, and reduce the risk to health-care workers,” said Kwok-Yung Yuen, a professor at the University of Hong Kong who co-led the research.

He said the lower risk to health workers would be due to the combination drug’s effect in reducing ‘viral shedding’ – which is when the virus is detectable and potentially transmissible.

In the trial, all patients received standard hospital care as needed, including ventilation support, dialysis support, antibiotics, and corticosteroids.

Kowk-Yung Yuen said the findings were “encouraging”, but that the triple drug’s effect now needed to be tested in larger numbers of patients and in people with more severe COVID-19 illness.

Independent experts agreed that the findings were positive, but said larger and more detailed studies would be needed.

This … definitely justifies the consideration of adding interferon beta to the list of genuinely, evidence-based, promising treatments to be tested in further randomized trials,” said Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine.

He said that long years of experience in treating the human immunodeficiency virus (HIV) that causes AIDS have shown that it is best treated with combinations of different drugs “and this could also be the case with COVID-19”.

Whatsapp Newsletter

Get free Updates on WhatsApp with our latest news every day.

1. Save our WhatsApp number +92 332 4646739 as a contact.
2. Send us a message with your full name to receive updates.
3. If you are already subscribed and want to stop receiving our updates please send the message ‘stop’.

Please note you have to save the number as a contact and send us a message to ensure subscription.

Support Us: If you like our post, please don’t forget to share this post with others to support us and also help others.

Sr # Channel Name Subscribe
1 Unique Vision Academy Click Here To Subscribe
2 Skilling Foundation Click Here To Subscribe
3 WordPress Tutorials Click Here To Subscribe
4 Diya Click Here To Subscribe
Sr # Facebook Page Name Like
1 Diya – Aao Roshni Philain Click Here To Like
2 Skilling Foundation Click Here To Like
3 Unique Vision Academy Click Here To Like
4 Stamflay Solutions Click Here To Like
5 Skilling Foundation Twitter Click Here To Follow
Sr # Contact Us
1 Call / WhatsApp +92-332-4646739
2 E-Mail Us at info@skilling.pk
3 E-Mail Us at info@diya.pk
4 Skilling Foundation Skilling.pk
5 Diya Diya.pk
6 To Get Free Latest Posts on Your Mobile Type Follow Skillingpk send to 40404

Note: Please send us Text Message or E-Mail If you didn’t reply soon please don’t call us, again and again, wait for your turn we will try to reply to you as soon as possible.

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.